The pulmonary arterial hypertension market was valued at USD 6.07 Billion in 2025, driven by rising aging population across the 8 major markets. The market is anticipated to grow at a CAGR of 5.00% during the forecast period of 2026-2035 to achieve a value of USD 9.89 Billion by 2035. The advent of new and innovative treatment alternatives for patients is one of the key growth drivers of the market.
Base Year
Historical Period
Forecast Period
The market is witnessing growth due to the rising prevalence of chronic respiratory and cardiovascular conditions worldwide.
Advancements in targeted therapies and combination treatments are driving improved patient outcomes and sustained market expansion.
Increasing healthcare spending and awareness in emerging economies are boosting early diagnosis and treatment adoption.
Compound Annual Growth Rate
5%
Value in USD Billion
2026-2035
*this image is indicative*
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterised by high blood pressure in the arteries that supply the lungs. It occurs when these arteries narrow or become blocked, making it harder for blood to flow through and forcing the heart to work harder. Over time, this can lead to heart failure. Symptoms include shortness of breath, fatigue, chest pain, and dizziness. PAH can be idiopathic or associated with other conditions like connective tissue disease. Although incurable, treatments can improve quality of life and slow disease progression. The market is anticipated to grow at a CAGR of 5.00% during the forecast period of 2026-2035.
Adoption of New Treatment Alternatives to Boost Market Value
Rising research collaborations and increasing investments in novel biologics are key drivers supporting the market development. For instance, in May 2025, the Imperial College London partnered with Apollo Therapeutics to advance a monoclonal antibody treatment for PAH. This innovative therapy, derived from university-led research, is undergoing proof-of-concept trials at Hammersmith Hospital. The treatment aims to alleviate symptoms and extend patient survival. It could significantly expand therapeutic options, driving long-term market growth through enhanced drug innovation and demand for disease-modifying treatments.
Rise in Regulatory Support to Meet Rising Pulmonary Arterial Hypertension Market Demand
Increasing regulatory support and rising demand for combination therapies are shaping the market dynamics. For instance, in December 2024, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved sotatercept for treating PAH in adults with moderate to severe physical limitations. The drug is administered alongside other medications to enhance exercise capacity. This approval strengthens the therapeutic landscape by introducing a novel mechanism of action. It is expected to stimulate market value during the forecast period through broader treatment accessibility and improved clinical outcomes.
Some of the notable trends include rising technical advancements, increasing emphasis on providing information to facilitate early detection, use of combination therapies for treatment, and rising regulatory approvals to bring innovative and effective solutions to the market.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Type
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Endothelin Receptor Antagonists to Dominate the Segmentation by Drug Class
Endothelin receptor antagonists are projected to lead the market due to their proven efficacy in lowering pulmonary vascular resistance. Their established role in first-line PAH therapy and strong clinical outcomes support their dominance. Market growth is further driven by continued research, new formulations, and broader adoption in early-stage PAH. As more patients receive early diagnoses, the demand for these antagonists is likely to rise, solidifying this segment’s strong market position during the forecast period.
Oral Administration to Lead the Market Share by Route of Administration
The oral route is expected to dominate due to its convenience, patient compliance, and reduced hospitalization rates. Oral therapies offer ease of use, especially for chronic conditions like PAH, where long-term treatment is essential. Pharmaceutical innovations are enhancing bioavailability and reducing side effects, contributing to growth. The expanding availability of oral fixed-dose combinations and broader access in outpatient settings will continue driving this segment’s market value in the coming years.
The U.S. remains the largest PAH market globally, driven by strong R&D, high healthcare spending, and early adoption of novel therapies. Key players like Johnson & Johnson (Janssen), United Therapeutics, and Gilead have significant presence. Government support, specialized treatment centers, and insurance coverage drive demand. However, high drug pricing and access disparities remain challenges. The UK PAH market benefits from the NHS framework, with centralized treatment protocols and specialized centers. Access to advanced therapies is relatively streamlined, though cost-effectiveness assessments by NICE can limit drug availability. The market is stable, with moderate growth expected through new therapeutic approvals and better diagnostics.
The key features of the market report comprise clinical trials analysis, patent analysis, grant analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Leverkusen, Germany, Bayer AG was founded in 1863. It is a global life sciences company with key operations in healthcare and agriculture. In the Pulmonary Arterial Hypertension (PAH) market, Bayer is recognised for Adempas (riociguat), the first soluble guanylate cyclase (sGC) stimulator approved for PAH and chronic thromboembolic pulmonary hypertension. Bayer actively invests in cardiovascular and pulmonary research, supporting its commitment to advanced treatment options for patients with PAH globally.
Founded in 1849 and headquartered in New York City, Pfizer Inc. is one of the world's premier biopharmaceutical companies. In the PAH market, Pfizer is noted for its development of Revatio (sildenafil), a phosphodiesterase-5 inhibitor used to improve exercise ability and delay clinical worsening in PAH patients. The company continues to explore next-generation therapies targeting rare cardiovascular conditions, maintaining a strong commitment to improving quality of life for those affected by pulmonary vascular diseases.
Established in 2000 and headquartered in London, United Kingdom, GSK plc (formerly GlaxoSmithKline) is a science-led global healthcare company. Within the PAH segment, GSK markets Flolan (epoprostenol sodium), an intravenous prostacyclin analogue for severe PAH cases. The company has also engaged in partnerships and research to explore advanced pulmonary therapies. GSK's focus on respiratory health and rare diseases underscores its strategic interest in addressing unmet medical needs in the PAH treatment landscape.
Founded in 1876 and based in Indianapolis, Indiana, Eli Lilly and Company is a leading global pharmaceutical firm. In the PAH market, Lilly is known for developing Adcirca (tadalafil), a once-daily phosphodiesterase-5 inhibitor, in partnership with United Therapeutics. The drug helps improve exercise capacity in patients with PAH. Lilly continues to invest in pulmonary and cardiovascular research, aligning with its long-standing mission to discover innovative treatments for serious chronic and rare conditions.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Actelion Pharmaceuticals (Johnson & Johnson), Amgen Inc., Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc., and Novartis AG.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Type |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share